Hyperfine, Inc. · NASDAQ:HYPR

Hyperfine — Q3 2026 Earnings Presentation

26 slides from Hyperfine's earnings presentation, Nov 9, 2026

  1. Slide 1: AI-Powered, Portable Brain MRI

    AI-POWERED, PORTABLE BRAIN MRI The Swoop® Portable MR Imaging System is Driving the Future of Brain Health Corporate Investor Deck – November 2026 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are tradema

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections

  3. Slide 3: Q3 2026: Inflection in a Strengthening Business

    Q3 2026: Inflection in a Strengthening Business Revenue Growth and Margin Expansion are Translating into Lower Cash Burn Q3 Results FY2026 Guidance1 Recent Milestones Strong Outlook $6.0M Revenue REVENUE · REAFFIRMED FDA Clearance & De-risked, Disruptive AI- Launch of AI Software Up 73% YoY and 53%

  4. Slide 4: Evolution of Brain Imaging

    Evolution of Brain Imaging Democratization, Decentralization, and Automation for Better Brain Health THE GATEWAY Restricted, Hospital-Centric Universal, Patient/Consumer Centric Hospital Shielded facility + Office • Concierge • Longevity • Mobile • Community Brain Care for disease management Brain C

  5. Slide 5: Hyperfine's Miniaturized MRI Technology Could Drive the Future of Imaging

    Hyperfine’s Miniaturized MRI Technology Could Drive the Future of Imaging A suite of proprietary imaging technologies and know-how that enable Miniaturized MRI for a full range of applications with proven usability & scalability More Than a Portable Brain MRI Company... 5 PROPERTY OF HYPERFINE. ©202

  6. Slide 6: The Swoop System Transforms and Expands the Reach of Brain Imaging

    The Swoop System Transforms and Expands the Reach of Brain Imaging Diagnostic Image Quality Portable, Compact Design Goes Simplified Set Up and Scanning for Clinicians Can Act On Directly to the Patient Broad Usability USING THE SWOOP SYSTEM IMPROVES MRI CAPACITY AND ACCESS WITH MEANINGFUL CLINICAL

  7. Slide 7: MRI is the Clinical Gold Standard, But Capacity and Access Are Limited

    MRI is the Clinical Gold Standard, But Capacity and Access Are Limited The MRI You Know The MRI You Wish For High-cost and complex site Significantly less expensive, no requirements limit access shielding or siting required. Available at any healthcare facility Need for highly trained No dedicated p

  8. Slide 8: Large Market Potential Bringing MRI to Multiple Sites of Care

    Large Market Potential Bringing MRI to Multiple Sites of Care Sizeable and Growing US TAM1 Through New Sites of Care $1.5B $6B+ $16B+ Inpatient Settings Outpatient Settings Community Settings 2023+ 2025+ 2026+ Adult critical care Emergency departments2 Urgent care facilities 4,000+ Peds critical car

  9. Slide 9: Addressing Critical Unmet Needs in Neurological Disease

    Addressing Critical Unmet Needs in Neurological Disease MRI access remains a critical gap — Swoop system brings point-of-care brain imaging to acute and chronic neurodegenerative conditions Sources: Published literature and company data on file. Stroke Dementia 12.2M 1.9M 1 in 4 55M+ 139M 2 in 3 new

  10. Slide 10: Solid Fundamentals: Accelerating Growth

    Solid Fundamentals: Accelerating Growth Development, Clinical & Early Compelling STRATEGY Commercial EXPANSION Commercial FOUNDATION • Model 2 Swoop System Launch • First Mover Advantage • Outstanding market feedback on Optive AI image quality Hospital Office International • Placements in all target

  11. Slide 11: How Close Are We to Conventional MRI?

    How Close Are We to Conventional MRI? 0.064T Swoop System 1.5 T Powered by Optive AI Software* Conventional MRI† 11 PROPERTY OF HYPERFINE ©2026. All rights reserved. * Sequence image acquired with Model 2 Swoop system hardware. † 1.5 T conventional MRI scans performed in 2018

  12. Slide 12: Image Quality of Next-Gen Swoop System to Drive Broad Adoption

    Image Quality of Next-Gen Swoop FLAIR (Swoop System) FLAIR (High-field 3T) System to Drive Broad Adoption Image Quality Approaching Conventional MRI Case Study of Swoop System vs. High-Field 3T 63-year-old female with history of prior infarct presenting with new-onset headache. Physicians performed

  13. Slide 13: AI-Enabled Imaging Software

    AI-Enabled Imaging Software Advanced, AI-driven image reconstruction to ultra-low field MRI—unlocking clearer images at lower field strengths Reduces noise and blur with deep learning, enhances image clarity and consistency, provides sharper anatomical detail to support confident diagnoses at the po

  14. Slide 14: Robust Commercial Growth Strategy Driven By Diversified Business Verticals

    Robust Commercial Growth Strategy Driven By 3 Diversified Business Verticals US NEUROLOGY OFFICE IAC Accreditation NEURO PMR CONTRAST PMR (Enrolled) INTERNATIONAL Initial UK/CE Initial India Model 2 Swoop Clearance Clearance UK/CE Clearance Critical Care Emergency Hospital IDNs US HOSPITAL (Adult &

  15. Slide 15: Hospital Business

    Hospital Business • Compelling clinical utility in critical care, emergency triage, neurosurgery and neuro follow up in adults & peds • Strong economic value proposition o Swoop system scans qualify for existing reimbursement (CPT 70551) o Opportunity to increase revenue, cost savings and optimized

  16. Slide 16: Office Business

    Office Business • A typical neurologist orders 500–600 MRIs annually1,2 for neurologic conditions such as headaches, dementia, tumor, MS, surgery follow-up • 90% of private neurology practices don’t have on-site MR imaging3 • Affordable and appealing, plug-and-play Swoop system o No specialized siti

  17. Slide 17: International Business

    International Business Model 1 Swoop system • Compelling clinical utility transferable globally • Selling primarily into the hospital setting, demonstrated value proposition in remote settings • Optive AI software launched in 10 European languages in Q1’26 • CE Mark and UKCA Mark approvals for the M

  18. Slide 18: Scalable Commercialization with US Direct Sales and Global Distribution Network

    Scalable Commercialization with US Direct Sales and Global Distribution Network INSTALLED BASE Over 225 Swoop Systems Globally1 DIRECT DISTRIBUTORS Dedicated Selling & Implementation Teams (~15 FTE in Total) 10+ Markets (2 FTE in Total) Healthy US Pricing & Recurring Revenue Swoop System Manufacture

  19. Slide 19: Multiple Catalysts Driving a Durable Revenue Trajectory

    Multiple Catalysts Driving a Durable Revenue Trajectory Model 2 Swoop system powered by Optive AI software Drivers & Catalysts Revenue ($M) $6.0 Ongoing 6 1 $5.3 • US rollout of Model 2 Swoop system & latest Optive AI software 5 • Growing adoption in ED, hospital clinics, and $3.9 $3.9 critical care

  20. Slide 20: Q3'26: Higher Revenue and Margins, Lower Cash Burn

    Q3’26: Higher Revenue and Margins, Lower Cash Burn $1.4M increase in gross profit with only $0.2M increase in operating expense versus Q2’26 $6.0M 56.7% $5.6M Revenue Gross Margin Net cash burn¹ 73% YoY growth 300 bps YoY expansion 6% YoY reduction 53% QoQ growth 600 bps QoQ expansion 29% QoQ reduct

  21. Slide 21: Revenue Growth, Margin Expansion and Cost Discipline Drive Operating Leverage

    Revenue Growth, Margin Expansion and Cost Discipline Drive Operating Leverage Revenue and gross-margin trends across seven quarters, with disciplined operating investment. REVENUE AND GROSS MARGIN Revenue nearly tripled while gross margin expanded 1,540 bps Gross margin 56.7% $6M 53.8% 50.9% +1,540

  22. Slide 22: Solid Financial Fundamentals

    Solid Financial Fundamentals FY26 Gross Margin Guidance Raised4; Cash Runway into 2028 REVENUE AND GROSS MARGIN CASH BURN1 FY26 OUTLOOK 4 Revenue FY26 Guidance Gross 25 margin % 2025 2026 GM%: Est. 52.5-55.0% $20–$22M 40 49.8% 0.52 Gross margin4 $20-$22M 0.47 35 52.5–55.0% 20 $29.9M 3 Net cash burn¹

  23. Slide 23: Platform Technology Expansion Opportunities

    Platform Technology Expansion Opportunities Hyperfine CORE Technology is Well Positioned to Deliver in Multiple Markets with Additional Growth and Value-added Services1 Now Next Future Expanded sequence offering Mobile for acute care Mobile brain health Neuro and private practice Expansion Contrast

  24. Slide 24: Leadership Team With Proven Track Record of Success

    Leadership Team With Proven Track Record of Success Maria Brett Hale Tom Rob Sainz Chief Administrative Teisseyre, PhD Fasciano, PhD President and Chief Officer and Chief Chief Operating Chief Regulatory Executive Officer Financial Officer Officer and Quality Officer Eric Rafael Donnay Chi Nguyen To

  25. Slide 25: Hyperfine, Inc. Opportunity

    Hyperfine, Inc. Opportunity Large TAM Strong Proprietary Broad Indications Prolific Innovation First-Mover Position and Applicability Engine • $16B+ US device market • Portable MR category • Brain imaging of • Image quality potential across leader patients of all ages approaching inpatient, outpatie

  26. Slide 26: AYPERFINE.

    AYPERFINE.

Hyperfine — Q3 2026 Earnings Presentation on 6ix